Ideally, future cellular mechanistic markers will give physicians a quantifiable measure to assess patient response to treatment, predict recurrence risk and patient survival, and guide patient counseling and tumor-specific treatment. Further mechanistic studies are needed to better understand CD44 and ALDH1A1 activity in OS. This evidence concerns the gene ALDH1A1 and neoplasm.